• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Summit Corporation plc - Product Pipeline Review - H2 2011 Product Image

Summit Corporation plc - Product Pipeline Review - H2 2011

  • Published: November 2011
  • 55 pages
  • Global Markets Direct

Summit Corporation plc – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Summit Corporation plc - Product Pipeline Review - H2 2011” provides data on the Summit Corporation plc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Summit Corporation plc’s corporate website, SEC filings, investor presentations and featured press releases, both from Summit Corporation plc and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Summit Corporation plc - Brief Summit Corporation plc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Summit Corporation plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various READ MORE >



List of Tables
List of Figures
Summit Corporation plc Snapshot
Summit Corporation plc Overview
Key Information
Key Facts
Summit Corporation plc – Research and Development Overview
Key Therapeutic Areas
Summit Corporation plc – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Summit Corporation plc – Pipeline Products Glance
Summit Corporation plc Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Summit Corporation plc–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Summit Corporation plc – Drug Profiles
Antiviral Program
Product Description
Mechanism of Action
R&D Progress
Drug for Tuberculosis
Product Description
Mechanism of Action
R&D Progress
Hepatatis C Program
Product Description
Mechanism of Action
R&D Progress
SMT 14224
Product Description
Mechanism of Action
R&D Progress
SMT C1100
Product Description
Mechanism of Action
R&D Progress
SMT C2100
Product Description
Mechanism of Action
R&D Progress
SMT D002
Product Description
Mechanism of Action
R&D Progress
Summit Corporation plc – Pipeline Analysis
Summit Corporation plc – Pipeline Products by Therapeutic Class
Summit Corporation plc - Pipeline Products By Target
Summit Corporation plc – Pipeline Products by Route of Administration
Summit Corporation plc – Pipeline Products by Molecule Type
Summit Corporation plc – Recent Pipeline Updates
Summit Corporation plc - Dormant Projects
Summit Corporation plc – Locations And Subsidiaries
Head Office
Recent Developments
Apr 15, 2008: Summit Plc Announces A Positive Phase I Clinical Trial Of SMT D002
Mar 14, 2011: Summit Reports Positive Non-Clinical Efficacy Results For SMT C1100 In Duchenne Muscular Dystrophy
May 12, 2011: Summit Announces Successful Achievement Of Further Research Milestone in C Difficile Program
Jan 12, 2010: Biomarin Initiates Phase I Clinical Study Of SMT C1100 For Duchenne Muscular Dystrophy
Dec 11, 2009: Summit plc., Awarded EUR 2.2million pounds from the Wellcome Trust
Jan 11, 2010: BioMarin Initiates Phase I Clinical Study Of BMN 195 For Duchenne Muscular Dystrophy
Sep 07, 2006: MNL Pharma Reports Positive Preclinical Data For Novel Anti-Fungal Compound MNLP1242
Sep 07, 2006: MNL Pharma Reports Positive Preclinical Data For Novel Anti-Fungal Compound MNLP1250
Aug 03, 2010: Summit Reports BioMarin's Decision To Discontinue Development Of BMN-195
Aug 02, 2010: BioMarin Announces Results For Phase I Clinical Study Of BMN 195 For Duchenne Muscular Dystrophy
Financial Deals Landscape
Summit Corporation plc, Deals Summary
Summit Corporation plc, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Summit Enters Into Co-Development Agreement With The Lilly TB Drug Discovery Initiative
Summit Enters Into Co-Development Agreement With Orient Pharma
Summit Enters Into Co-Development Agreement With Evolva Biotech
Licensing Agreements
Summit Enters Into Licensing Agreement With Evolva Biotech
BioMarin Pharmaceutical Enters Into Worldwide Licensing Agreement With Summit
Equity Offering
Summit Completes Private Placement Of Common Stock For $2.2 Million
Summit Completes Placement Of $13.34 Million
Summit Completes Private Placement Of $7.1 Million
Summit Corporation Completes Placement Of $18.24 Million
Asset Transactions
Evotec Acquires Zebrafish Screening Operations From Summit
BioMarin Pharmaceutical Acquires Rights Of SMT C1100 From Summit
Acquisition
Summit Sells Dextra Laboratories To New Zealand Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Summit Corporation plc – Pipeline by Therapy Area and Indication, H2 2011
Summit Corporation plc – Pipeline by Stage of Development, H2 2011
Summit Corporation plc – Monotherapy Products in Pipeline, H2 2011
Summit Corporation plc - Phase I, H2 2011
Summit Corporation plc - Pipeline By Therapeutic Class, H2 2011
Summit Corporation plc - Pipeline By Target, H2 2011
Summit Corporation plc – Pipeline By Route of Administration, H2 2011
Summit Corporation plc – Pipeline By Molecule Type, H2 2011
Summit Corporation plc – Recent Pipeline Updates, H2 2011
Summit Corporation plc - Dormant Developmental Projects, 2010
Summit Corporation plc, Deals Summary
Summit Enters Into Co-Development Agreement With The Lilly TB Drug Discovery Initiative
Summit Enters Into Co-Development Agreement With Orient Pharma
Summit Enters Into Co-Development Agreement With Evolva Biotech
Summit Enters Into Licensing Agreement With Evolva Biotech
BioMarin Pharmaceutical Enters Into Worldwide Licensing Agreement With Summit
Summit Completes Private Placement Of Common Stock For $2.2 Million
Summit Completes Placement Of $13.34 Million
Summit Completes Private Placement Of $7.1 Million
Summit Corporation Completes Placement Of $18.24 Million
Evotec Acquires Zebrafish Screening Operations From Summit
BioMarin Pharmaceutical Acquires Rights Of SMT C1100 From Summit
Summit Sells Dextra Laboratories To New Zealand Pharmaceuticals

List of Figures
Summit Corporation plc – Pipeline by Therapy Area and Indication, H2 2011
Summit Corporation plc – Pipeline by Stage of Development, H2 2011
Summit Corporation plc – Monotherapy Products in Pipeline, H2 2011
Summit Corporation plc – Pipeline By Therapeutic Class, H2 2011
Summit Corporation plc - Pipeline By Target, H2 2011
Summit Corporation plc – Pipeline By Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS